Breaking News Instant updates and real-time market news.

DVA

DaVita

$54.62

2.08 (3.96%)

, FMS

Fresenius Medical

$38.23

0.75 (2.00%)

12:16
07/10/19
07/10
12:16
07/10/19
12:16

Trump signs executive order encouraging home dialysis, kidney transplants

President Trump today signed an executive order "aimed at improving kidney health and promoting increased treatment options for American patients." Under the executive order, Medicare will test adjusting payment incentives to encourage preventative kidney care and the use of home dialysis and kidney transplants. President Trump is also directing his Administration "to develop a process to get artificial kidneys to patients in order to encourage development of such technology." The statement from the White House reads, "The current quality of care for patients with kidney disease is unacceptable and treatment options are far too expensive." Shares of both Davita (DVA) and Fresenius Medical Care (FMS), which have been down this week in anticipation of today's news, are up 4% and 2%, respectively, in midday trading. CareDx (CDNA), which develops diagnostic solutions for transplant recipients, are up 3% to $39.58. Providers of home health services, including LHC Group (LHCG) and Amedisys (AMED) are also higher in midday trading. Reference Link

DVA

DaVita

$54.62

2.08 (3.96%)

FMS

Fresenius Medical

$38.23

0.75 (2.00%)

CDNA

CareDx

$39.55

0.955 (2.47%)

LHCG

LHC Group

$121.92

1.11 (0.92%)

AMED

Amedisys

$121.62

0.93 (0.77%)

  • 08

    Aug

  • 10

    Sep

  • 17

    Sep

  • 18

    Sep

  • 19

    Sep

  • 25

    Sep

  • 02

    Oct

  • 03

    Oct

  • 13

    Nov

DVA DaVita
$54.62

2.08 (3.96%)

02/15/19
BARD
02/15/19
NO CHANGE
Target $70
BARD
Outperform
DaVita price target lowered to $70 from $90 at Baird
Baird analyst Matthew Gillmor lowered his price target on DaVita to $70 from $90 and acknowledged it remains a controversial stock. The analyst said underlying demand appears to be slowing, but that valuation is undemanding and already reflects significant earnings risk. Although Gillmor said his enthusiasm for DaVita has waned recently, he believes it still has a favorable setup and thus maintained his Outperform rating on the shares.
01/09/19
RBCM
01/09/19
NO CHANGE
Target $65
RBCM
Sector Perform
DaVita price target lowered to $65 from $78 at RBC Capital
RBC Capital analyst Frank Morgan lowered his price target on DaVita to $65 and also reduced his FY19 EPS view to $3.93 from $4.12 after its management provided initial FY19 operating income outlook of $1.54B-$1.64B relative to consensus of $1.62B. The analyst notes that the company's near term is likely to be impacted by "industry headline risk, potential margin pressures due to increased scrutiny of dialysis rates, and ongoing labor cost growth", but sees dialysis as a "steady, stable, defensive industry over the long term, with predictable patient volumes and strong cash flows".
01/08/19
UBSW
01/08/19
UPGRADE
UBSW
Neutral
DaVita upgraded to Neutral from Sell at UBS
01/08/19
UBSW
01/08/19
UPGRADE
Target $59
UBSW
Neutral
UBS upgrades DaVita to Neutral on better risk/reward profile
UBS analyst Whit Mayo upgraded DaVita to Neutral from Sell while lowering his price target for the shares to $59 from $64. The recent weakness in the shares drives a better risk/reward profile, Mayo tells investors in a research note. The analyst, however, continues to sees structural concerns with payer mix and points out that record industry capacity is for sale.
FMS Fresenius Medical
$38.23

0.75 (2.00%)

06/20/19
LEHM
06/20/19
UPGRADE
LEHM
Overweight
Fresenius Medical upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Hassan Al-Wakeel upgraded Fresenius Medical Care to Overweight from Equal Weight and raised his price target for the shares to 81.50 euros from 71 euros. After speaking with CEO Rice Powell and a deep-dive into U.S. dialysis market fundamentals, the analyst believes market concerns around the medium-term sustainability of growth are likely overdone. The analyst has started to see some improvements in the business and believes expectations are now achievable. He now sees a "compelling" risk/reward over the medium term for shares of Fresenius Medical.
10/26/18
UBSW
10/26/18
UPGRADE
UBSW
Buy
Fresenius Medical upgraded to Buy from Neutral at UBS
UBS analyst Ian Douglas-Pennant upgraded Fresenius Medical to Buy while lowering his price target for the shares to EUR 82 from EUR 86. The analyst says the Q3 pre-release selloff presents a buying opportunity.
02/21/19
RHCO
02/21/19
NO CHANGE
Target $48
RHCO
Buy
Fresenius Medical price target raised to $48 from $40 at SunTrust
SunTrust analyst David MacDonald raised his price target on Fresenius Medical to $48 and kept his Buy rating after its Q4 results yesterday, saying the quarter was "marked by solid organic trends, ongoing efficiency gains and strong cash flow." The analyst anticipates the company's 2019 to be a year of investment but sees the incremental spending driving more optimization and positioning Fresenius Medical for "attractive growth opportunities". MacDonald adds that he is positive on the company's pending acquisition of NxStage Medical (NXTM) given the market shift "towards the home".
11/20/18
RHCO
11/20/18
NO CHANGE
Target $46
RHCO
Buy
Fresenius Medical price target lowered to $46 from $62 at SunTrust
SunTrust analyst David MacDonald lowered his price target on Fresenius Medical to $46 to reflect its "soft" Q3 results with a lower implied valuation of 10-times forward EBITDA. The analyst believes that given the mixed fundamentals, the stock is a "show me" story, even though he keeps his Buy rating on Fresenius Medical longer term based on its "solid core volume trends, attractive overarching industry drivers, a diversified business model, and strong free cash generation".
CDNA CareDx
$39.55

0.955 (2.47%)

07/10/19
RAJA
07/10/19
NO CHANGE
Target $46
RAJA
Strong Buy
CareDx should get 'Trump Bump' from kidney care speech, says Raymond James
Noting that President Donald Trump is expected to discuss policies to increase the volume of organ transplants, including kidneys by 17,000 over time, in a speech scheduled for 11 am ET this morning, Raymond James analyst John Hsu said he anticipates a positive tailwind for organ transplants and a "Trump Bump" for CareDx. While Hsu said he thinks a target to nearly double the current kidney transplant rate is "undoubtedly an ambitious goal" and he sees a 13-15% increase in year one as more likely, he raised his revenue estimates for CareDx given an expected acceleration from the 5% typical increase in annual kidney transplants. He maintains a Strong Buy rating and $46 price target on CareDx shares.
05/09/19
HCWC
05/09/19
UPGRADE
Target $43
HCWC
Buy
CareDx upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju upgraded CareDx to Buy from Neutral and raised his price target for the shares to $43 from $30. The company in Q1 posted positive EBITDA for the third consecutive quarter, Selvaraju tells investors in a research note. The analyst believes CareDx could achieve positive EBITDA sustainably going forward.
05/09/19
PIPR
05/09/19
NO CHANGE
Target $50
PIPR
Overweight
CareDx price target raised to $50 from $42 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for CareDx to $50 from $42 following the company's better than expected Q1 results and increased outlook. CareDx has widened its "competitive moat" in transplant medicine with KidneyCare, Quirk tells investors in a research note. The stock remains his top small cap idea with an Overweight rating.
03/28/19
RAJA
03/28/19
NO CHANGE
RAJA
Strong Buy
CareDx lawsuit against Natera 'not unexpected,' says Raymond James
Raymond James analyst John Hsu notes that CareDx (CDNA) announced the filing of a patent infringement lawsuit against Natera (NTRA), which was "not unexpected." The analyst sees the lawsuit as consistent with management seeking to protect the company's intellectual property, and notes that the court process could take up to three years. While this lawsuit is a "logical course of action," Hsu believes CareDx remains focused on building its moat in kidney transplant, with sales force investments and a focus on integration with hospital electronic medical records. Overall, the analyst still views 2019's main focus on other activities to strengthen a "significant head start on the back of a best-in-class product launch in 2018." He reiterates a Strong Buy rating on CareDx shares.
LHCG LHC Group
$121.92

1.11 (0.92%)

03/01/19
RHCO
03/01/19
NO CHANGE
Target $130
RHCO
Buy
LHC Group price target raised to $130 from $115 at SunTrust
SunTrust analyst David MacDonald raised his price target on LHC Group to $130 and kept his Buy rating after its Q4 results. The analyst says the quarter was driven by strong organic volumes, better than expected integration of Almost Family, solid cash flow trends, and the ongoing M&A / joint venture activities.
05/13/19
RBCM
05/13/19
NO CHANGE
Target $130
RBCM
Outperform
LHC Group price target raised to $130 from $120 at RBC Capital
RBC Capital analyst Frank Morgan raised his price target on LHC Group to $130 and kept his Outperform rating after its "solid" Q1 results and raised FY19 guidance. The analyst cites the company's ongoing organic volume growth in home health and hospice along with synergy capture from Almost Family proceeding ahead of schedule, with the merger creating "the largest independent provider of in-home services" in the market. Morgan believes that LHC Group is well positioned to produce strong earnings growth for the next few years.
05/09/19
JEFF
05/09/19
NO CHANGE
Target $130
JEFF
Buy
LHC Group price target raised to $130 from $125 at Jefferies
Jefferies analyst Brian Tanquilut raised his price target for LHC Group to $130 from $125 and keeps a Buy rating on the shares following the company's Q1 results. In a post-earnings research note titled "Playoff Games Aren't Won or Lost in Q1; Focus on Strong Margins, Guidance Raise," Tanquilut says he does not think investors should view the Q1 revenue shortfall as a sign of fundamental softening, especially given the 10 basis point margin beat versus consensus.
03/01/19
CHLM
03/01/19
NO CHANGE
Target $114
CHLM
Hold
LHC Group price target raised to $114 from $93 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich maintained a Hold rating on LHC Group and raised his price target to $114 from $93 following the company's mixed quarterly results. In a research note to investors, Ellich says he remains optimistic about several factors including that the integration of Almost Family integration is ~6 months ahead of schedule and synergies are exceeding prior expectations and LHC's JV pipeline could accelerate throughout the year following the Geisinger and AtlantiCare Home Health and Hospice deal announced earlier this week which will add ~$35M of annual revenue. Despite these factors, Ellich believes valuation and the PDGM overhang will keep LHC range-bound in the near-term.
AMED Amedisys
$121.62

0.93 (0.77%)

05/02/19
RAJA
05/02/19
UPGRADE
RAJA
Outperform
Amedisys upgraded to Outperform from Market Perform at Raymond James
03/01/19
CHLM
03/01/19
NO CHANGE
Target $124
CHLM
Hold
Amedisys price target cut to $124 from $132 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich maintained a Hold rating on Amedisys and cut his price target to $124 from $132 following the company's Q4 results. In a research note to investors, Ellich says that while CCH's EBITDA contribution is expected to ramp from $12M-$14M in 2019 to ~$50M in 2021, and Amedisys has ample dry powder for acquisitions and share repurchases, he believes its premium valuation and the overhang attributable to PDGM will continue to weigh on the stock in the near-term.
07/08/19
JEFF
07/08/19
NO CHANGE
Target $150
JEFF
Buy
Amedisys long-term prospects 'compelling,' says Jefferies
After hosting meetings with management, Jefferies analyst Brian Tanquilut has "increased appreciation" for Amedisys' "compelling" long-term prospects. Management did a good job of explaining why home nursing will outperform overall healthcare sector growth going forward, Tanquilut tells investors in a research note. The analyst points to Medicare population growth and the increasing percentage of hospital discharges to home. Further, home nursing is one of few beneficiaries if Medicare for All happens, says the analyst. He believes potential rate cuts from upcoming Medicare rule changes should be mitigatable and keeps a Buy rating on Amedisys with a $150 price target.
03/01/19
RHCO
03/01/19
NO CHANGE
Target $145
RHCO
Buy
Amedisys price target raised to $145 from $135 at SunTrust
SunTrust analyst David MacDonald raised his price target on Amedisys to $145 and kept his Buy rating after its Q4 earnings beat. The analyst says the results were driven by "strong core trends, solid organic volumes, and ongoing operational improvement". MacDonald also cites the company's strong cash flow, with added opportunities coming from its "enviable" strategic positioning as medical care moves toward the home.

TODAY'S FREE FLY STORIES

CBS

CBS

$43.83

0.5 (1.15%)

, VIA

Viacom

$27.27

-0.4 (-1.45%)

08:03
08/17/19
08/17
08:03
08/17/19
08:03
Periodicals
Viacom-CBS merger got panned by investors, Barron's says »

CBS (CBS) and Viacom…

CBS

CBS

$43.83

0.5 (1.15%)

VIA

Viacom

$27.27

-0.4 (-1.45%)

VIAB

Viacom

$26.02

0.09 (0.35%)

AAPL

Apple

$206.44

4.71 (2.33%)

DIS

Disney

$135.19

1.79 (1.34%)

T

AT&T

$34.98

0.64 (1.86%)

CMCSA

Comcast

$43.17

0.82 (1.94%)

CMCSK

Comcast

$0.00

(0.00%)

NFLX

Netflix

$302.74

6.81 (2.30%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 05

    Sep

  • 23

    Sep

  • 23

    Oct

  • 27

    Oct

MYGN

Myriad Genetics

$25.36

2.14 (9.22%)

07:57
08/17/19
08/17
07:57
08/17/19
07:57
Periodicals
Myriad Genetics stock might have an FDA issue, Barron's says »

Myriad Genetics plunged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CSCO

Cisco

$46.96

0.73 (1.58%)

, NTAP

NetApp

$46.75

0.33 (0.71%)

07:50
08/17/19
08/17
07:50
08/17/19
07:50
Periodicals
Trade war hitting tech stocks, Barron's says »

Cisco (CSCO) plunged 9% a…

CSCO

Cisco

$46.96

0.73 (1.58%)

NTAP

NetApp

$46.75

0.33 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 12

    Sep

  • 10

    Oct

  • 13

    Nov

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

, RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

07:47
08/17/19
08/17
07:47
08/17/19
07:47
Periodicals
Investors should not abandon oil, gas stocks, Barron's says »

Energy stocks have rarely…

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

BP

BP

$36.27

0.22 (0.61%)

XOM

Exxon Mobil

$68.30

1.06 (1.58%)

CVX

Chevron

$115.79

0.08 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 25

    Sep

TGT

Target

$84.20

1.67 (2.02%)

, WMT

Walmart

$112.99

0.32 (0.28%)

07:40
08/17/19
08/17
07:40
08/17/19
07:40
Periodicals
Grocery Outlet thriving as rivals struggle, Barron's says »

While Dow was down 800…

TGT

Target

$84.20

1.67 (2.02%)

WMT

Walmart

$112.99

0.32 (0.28%)

GO

Grocery Outlet

$46.55

2.81 (6.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

AEO

American Eagle

$15.40

0.63 (4.27%)

07:33
08/17/19
08/17
07:33
08/17/19
07:33
Periodicals
American Eagle to soar despite trade war, Barron's says »

American Eagle's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 25

    Sep

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

, MTCH

Match Group

$84.53

2.08 (2.52%)

07:27
08/17/19
08/17
07:27
08/17/19
07:27
Periodicals
Dating business might be IAC's best asset, greatest challenge, Barron's says »

IAC (IAC) has rallied 34%…

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

MTCH

Match Group

$84.53

2.08 (2.52%)

IAC

IAC

$249.17

4.21 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 10

    Sep

  • 10

    Oct

AAPL

Apple

$206.44

4.71 (2.33%)

, HAS

Hasbro

$114.29

1.13 (1.00%)

07:13
08/17/19
08/17
07:13
08/17/19
07:13
On The Fly
Week in review How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$206.44

4.71 (2.33%)

HAS

Hasbro

$114.29

1.13 (1.00%)

MAT

Mattel

$10.74

(0.00%)

AGR

Avangrid

$49.29

0.37 (0.76%)

JPM

JPMorgan

$107.73

2.52 (2.40%)

BAC

Bank of America

$27.04

0.79 (3.01%)

C

Citi

$63.46

2.13 (3.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 09

    Sep

  • 02

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 27

    Oct

NCLH

Norwegian Cruise Line

$50.48

1.38 (2.81%)

18:04
08/16/19
08/16
18:04
08/16/19
18:04
Hot Stocks
Norwegian Cruise Line CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RM

Regional Management

$27.12

0.14 (0.52%)

18:01
08/16/19
08/16
18:01
08/16/19
18:01
Hot Stocks
Regional Management CFO buys 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

RTN

Raytheon

$178.10

-0.42 (-0.24%)

17:59
08/16/19
08/16
17:59
08/16/19
17:59
Hot Stocks
Raytheon awarded $199.59M Navy contract for MK 15 CIWS »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEN

Wendy's

$19.94

0.16 (0.81%)

17:57
08/16/19
08/16
17:57
08/16/19
17:57
Hot Stocks
Breaking Hot Stocks news story on Wendy's »

Trian Fund lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

BRY

Berry Petroleum

$8.59

0.39 (4.76%)

17:54
08/16/19
08/16
17:54
08/16/19
17:54
Syndicate
Breaking Syndicate news story on Berry Petroleum »

Berry Petroleum files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSWI

CSW Industrials

$70.20

1.92 (2.81%)

17:52
08/16/19
08/16
17:52
08/16/19
17:52
Hot Stocks
CSW Industrials CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OAS

Oasis Petroleum

$3.03

0.135 (4.66%)

17:49
08/16/19
08/16
17:49
08/16/19
17:49
Hot Stocks
Oasis Petroleum CEO buys 30K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EE

El Paso Electric

$66.41

0.005 (0.01%)

17:45
08/16/19
08/16
17:45
08/16/19
17:45
Hot Stocks
El Paso Electric director Wertheimer sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HON

Honeywell

$165.07

2.81 (1.73%)

17:42
08/16/19
08/16
17:42
08/16/19
17:42
Hot Stocks
Honeywell CEO sells 7.1K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBRX

Moleculin Biotech

$1.08

0.01 (0.93%)

17:37
08/16/19
08/16
17:37
08/16/19
17:37
Earnings
Moleculin Biotech reports Q2 EPS (3c), two estimates (10c) »

CFO Jonathan Foster…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIVE

Viveve

$0.13

0.0046 (3.59%)

17:35
08/16/19
08/16
17:35
08/16/19
17:35
Syndicate
Breaking Syndicate news story on Viveve »

Viveve files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRGO

Perrigo

$46.21

0.535 (1.17%)

17:30
08/16/19
08/16
17:30
08/16/19
17:30
Hot Stocks
Breaking Hot Stocks news story on Perrigo »

Starboard lowers Perrigo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

UAL

United Continental

$82.96

1.36 (1.67%)

17:28
08/16/19
08/16
17:28
08/16/19
17:28
Hot Stocks
United Continental director Shapiro buys 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 05

    Sep

  • 23

    Sep

MBIO

Mustang Bio

$3.88

0.19 (5.15%)

17:26
08/16/19
08/16
17:26
08/16/19
17:26
Syndicate
Breaking Syndicate news story on Mustang Bio »

Mustang Bio files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

BCLI

BrainStorm

$3.63

0.055 (1.54%)

17:24
08/16/19
08/16
17:24
08/16/19
17:24
Syndicate
Breaking Syndicate news story on BrainStorm »

BrainStorm files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLK

Westlake Chemical

$61.27

0.66 (1.09%)

17:15
08/16/19
08/16
17:15
08/16/19
17:15
Hot Stocks
Westlake Chemical raises quarterly dividend by 5% to 26.25c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIG

GigCapital

$10.30

(0.00%)

17:10
08/16/19
08/16
17:10
08/16/19
17:10
Hot Stocks
GigCapital receives noncompliance notice from NYSE »

GigCapital announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.